AVXL vs. BHVN, MTSR, ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, and BHC
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Biohaven (BHVN), Metsera (MTSR), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs.
Biohaven (NYSE:BHVN) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
Biohaven currently has a consensus target price of $62.77, indicating a potential upside of 121.38%. Anavex Life Sciences has a consensus target price of $44.00, indicating a potential upside of 361.22%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Biohaven.
Anavex Life Sciences received 33 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 74.79% of users gave Anavex Life Sciences an outperform vote while only 67.33% of users gave Biohaven an outperform vote.
In the previous week, Biohaven had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 6 mentions for Biohaven and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.54 beat Biohaven's score of 0.81 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
Biohaven has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
88.8% of Biohaven shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 16.0% of Biohaven shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Anavex Life Sciences' return on equity of -37.50% beat Biohaven's return on equity.
Anavex Life Sciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summary
Anavex Life Sciences beats Biohaven on 9 of the 15 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy AVXL Stock Free AVXL Stock Alerts